Inhibition of Transforming Growth Factor (TGF)-β1–Induced Extracellular Matrix with a Novel Inhibitor of the TGF-β Type I Receptor Kinase Activity: SB-431542
GlaxoSmithKline (United Kingdom) · GlaxoSmithKline (United States)
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
650
total citations
- FWCI
- 9.05
- Percentile
- 100%
- References
- 44
Citations per year
Authors
13- NJNicholas J. LapingCorresponding
GlaxoSmithKline (United Kingdom)
- ETEugene T. Grygielko
GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States)
- AMAnil Mathur
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
- SBSebastian Butter
GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
- JMJennifer M. Bomberger
GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States)
Topics & keywords
Topics
Keywords
- SMAD
- MAPK/ERK pathway
- Kinase
- Protein kinase A
- Cell biology
- Transforming growth factor
- Chemistry
- p38 mitogen-activated protein kinases
No related works found for this paper.